STANDARD BIOTOOLS INC. reported the quarter ended March 31, 2026 results: revenue $21.1 million, net income $14.6 million. Guidance reaffirmed.
“(NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026. Recent Highlights: • First quarter 2026 revenue of $21.1 million • 54% reduction in operating loss and 78% improvement in adjusted EBITDA year-over-year supporting path to positive adjusted EBITDA exiting 2026 • $524 million in cash &”
Listing & Compliance Notices
STANDARD BIOTOOLS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 20, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) in”
M&A Transactions
STANDARD BIOTOOLS INC. completed a disposition involving Illumina, Inc. for $350 million in upfront cash and up to $75 million in earnout payments for aggregate cash consideration of up to $425 million (closed 2026-01-30).
“which are being retained by the Company. Under the terms of the Purchase Agreement, Purchaser acquired the Shares for aggregate cash consideration of up to $425 million, comprising (i) an upfront payment of $350 million in cash, which was paid at the closing of the Transaction, as adjusted in accordance with the terms of the Purchase Agreement”
Restructurings & Charges
STANDARD BIOTOOLS INC. announced a restructuring with charges of approximately $7.5 million (approximately 15% of its total global workforce).
“The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $7.5 million. These estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that”
Restructurings & Charges
STANDARD BIOTOOLS INC. announced a restructuring with charges of approximately $3.6 million affecting R&D function (reduction-in-force of certain U.S. employees in the Company’s R&D function, including members of its management team).
“The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $3.6 million, which includes approximately $0.9 million of non-cash expenses related to vesting of share-based awards. These estimates are subject to a number of assumptions, and actual”
Jeremy Davis departed as Chief Commercial Officer at STANDARD BIOTOOLS INC..
“On January 3, 2025, Standard BioTools Inc. (the “Company”) and Jeremy Davis, the Company’s Chief Commercial Officer, mutually determined that Mr. Davis will no longer serve in such position, effective as of February 1, 2025.”
Alex Kim was appointed as Chief Financial Officer at STANDARD BIOTOOLS INC..
“On November 6, 2024, the Board of Directors of Standard BioTools Inc. (the “Company”) appointed Alex Kim, who has been serving as the Company’s Interim Chief Financial Officer since September 1, 2024, as the Company’s fulltime Chief Financial Officer, effective as of November 11, 2024 (the “Effective Date”).”
Alex Kim was appointed as Interim Chief Financial Officer at STANDARD BIOTOOLS INC..
“On July 30, 2024, the Company’s Board of Directors appointed Alex Kim, the Company’s Chief Operating Officer, to serve as Interim Chief Financial Officer of the Company, starting on September 1, 2024, to succeed Mr. Black while the Company searches for a permanent Chief Financial Officer.”
Jeffrey Black resigned as Senior Vice President and Chief Financial Officer at STANDARD BIOTOOLS INC..
“On July 26, 2024, Jeffrey Black resigned as the Senior Vice President and Chief Financial Officer (serving as the principal financial and accounting officer) of Standard BioTools Inc. (the “Company”), effective as of August 31, 2024.”
Earnings Releases
STANDARD BIOTOOLS INC. reported the three months ended March 31, 2024 results: revenue $45.5 million, net income $(32.2) million. Guidance reaffirmed.
“On May 8, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2024.”
Restructurings & Charges
STANDARD BIOTOOLS INC. announced a restructuring with charges of Streamlined Operational Expenditures including closure of the Company's R&D facility in San Diego, reductions in SG&A expenses, and savings related to a more pr affecting R&D facility in San Diego and overall SG&A expenses.
“Streamlined Operational Expenditures: Includes reductions in overall selling, general and administrative (SG&A) expenses, the closure of the Company’s R&D facility in San Diego, as well as savings related to a more prioritized R&D strategy.”
Restructurings & Charges
STANDARD BIOTOOLS INC. announced a restructuring with charges of Reduction-in-force of approximately 10% of total workforce, including elimination of certain senior management positions, with expected expenses of $10 million affecting total workforce (approximately 10% of its total workforce).
“On April 25, 2024, Standard BioTools Inc. (the “Company”) announced a reduction-in-force of approximately 10% of its total workforce, including the elimination of certain senior management positions following the closing of the Company’s merger with SomaLogic, Inc., as part of an operational restructuring plan.”
Governance Changes
STANDARD BIOTOOLS INC.: Eliminated Series B Preferred Stock designations from the Certificate of Incorporation via Certificates of Elimination (effective 2024-03-18).
“On March 18, 2024, following the closing of the Exchange, the Company filed a Certificate of Elimination of Series B-1 Convertible Preferred Stock and a Certificate of Elimination of Series B-2 Convertible Preferred Stock (together, the “Certificates of Elimination”) with the Secretary of State of the State of Delaware.”
Material Agreements
STANDARD BIOTOOLS INC. entered into Exchange Agreement with Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P., Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP (effective 2024-03-18).
“On March 18, 2024, Standard BioTools Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Casdin Private Growth Equity Fund II, L.P., Casdin Partners Master Fund, L.P., Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP (each, an “Investor” and, collectively, the “Investors”).”
Earnings Releases
STANDARD BIOTOOLS INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $28.2, net income $(19.8).
“2023 Fourth Quarter and Full Year Selected Financial Results 2 Quarter Ended Year Ended (Unaudited, in millions, except percentages) December 31, 2023 December 31, 2023 Revenue $ 28.2 $ 106.3 GAAP gross margin 47.4 % 47.4 % Non-GAAP gross margin 59.6 % 60.1 % Operating expenses $ 34.7 $ 127.1 Non-GAAP operating expenses $ 24.3 $ 98.6 Operating loss $ (21.4 ) $”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.